TBI 302

Drug Profile

TBI 302

Alternative Names: HRC 204; TBI-302

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hemosol BioPharma
  • Developer Therapure Biopharma
  • Class Antineoplastics; Deoxyribonucleosides; Drug conjugates; Haemoglobins; Nucleosides; Pyrimidine nucleosides
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatocellular carcinoma
  • No development reported Colorectal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in Canada (IV, Infusion)
  • 07 Apr 2016 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical study in Hepatocellular carcinoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 25 Mar 2015 US FDA approves IND application for TBI 302 in Hepatocellular carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top